Aller au contenu principal
Fermer

Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
information fournie par Boursorama CP 01/10/2021 à 15:00
Ajouter Boursorama à vos sources

Strasbourg, France, and Lund, Sweden, October 1, 2021, 3:00 pm CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce that they will present additional preclinical data on their novel dual mechanism-of-action oncolytic vaccinia virus BT-001 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC2021) in November 2021.

.../...

Valeurs associées

0,8540 EUR Euronext Paris -0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.

98,82 +0,27%
8 154,91 +0,20%
Or
4 337,4 -0,42%
1,14362 -0,12%
78,15 -0,52%
Chargement...